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Reprogramming of somatic cells to obtain induced pluripotent stem cells (iPSC) was achieved for the first 
time by Shinya Yamanaka and Kazutoshi Takahashi (2006). Since then, there have been developed many 
different methods to reprogram somatic cells into iPSCs.  All these techniques require incorporation of the 
reprogramming factors  (with different delivery methods and factor combinations) into a somatic cell 
type. 
 
The reprogramming process involves choosing a suitable reprogramming factors “cocktail”, cell type and 
method. The main problem of the methods used for generation iPSC is their low efficiency, but also other 
ones (screening problems, tumor, etc). Nowadays iPSCs research lines are routed to their use for 
medicine, not yet known if they will fit this goal. 
 
This poster shows an overview of all these aspects and explains currently used methods for generating 
iPSC (including their advantages, disadvantages and average efficiency). 
  
 
 
 
MMLV retrovirus: Using a retrovirus to deliver the reprogramming 
factors was the first method to be used. STEPS: (1) Infection with 
single/polycistronic retrovirus; (2) Factor delivery;  
(3) Reprogramming; (4) Differentiation. 
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Lentivirus: Different modified lentivirus can be used to deliver the 
reprogramming factors in a more controlled  manner, specially with 
DOX-inducible promoter and Cre recombinase. STEPS: (1) Infection 
with constitutive/DOX-inducible/Excisable lentiviruses (respectively); 
(2) Factor delivery; (3) Reprogramming; (4) Differentiation. 
Sendai virus:  This ssRNA (-) virus does not integrate in the genome 
and has shown to be a very good method for iPSC production.  
(1) Infection with Sendai virus; (2) Reprogramming; (3) Differentiation. 
Piggybac transposon/Lineal DNA transfection: Using excisable 
vectors, reprogramming factors can be easily removed after 
integration. STEPS: (1) Liposome/electroporation to insert the vector 
into cells; (2) Reprogramming (loosing vector); (3) Differentiation. 
Transcient episomal delivery: Reprogramming factors transfected in 
plasmid vectors (single/polycistronic).STEPS: (1) Liposome/ 
electroporation to introduce the plasmid into cells; (2) 
Reprogramming  and vector lost by dilution. 
Protein delivery: Reprogramming can be achieved by introducing the 
factors (as proteins) directly to the cells. STEPS: (1) Introduction of 
modified reprogramming factors directly to cells; (2) Reprogramming; 
(3) Differentiation. 
RNA delivery:  Delivering modified RNA can induce a very efficient 
method causing translation of reprogramming factors. STEPS: (1) 
Introduction of modified RNA to cells; (2) Reprogramming; (3) 
Differentiation. 
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•Very efficient 
infection (~90%) 
•Stable. 
 
 
 
 
 
 
 
 
 
 
•Very stable. 
 
 
 
•Very stable. 
 
 
 
 
•Transgene-free. 
 
 
 
 
 
 
 
•Integration-free. 
•Easy screening (HN 
protein). 
•Multiple viral 
integrations. 
•Transgenes remain in 
the genome. 
•Partially 
reprogrammed iPSC. 
 
 
 
 
 
 
 
•Genome integration. 
•Residual expression 
of the transgenes. 
•Low efficiency. 
 
 
•Genome integration. 
 
 
•Requires specific 
recombinases and 
safe insertion sites. 
•Little scar on the 
genome. 
 
 
 
 
 
•Special facilities 
required for Sendai 
virus. 
 
 
 
•Transgene-free and 
vector-free. 
•Reproducible.  
 
 
 
•Transgene-free and 
vector-free. 
 
 
 
 
 
 
 
•Transgene-free and 
vector-free. 
•No genomic 
integration. 
•Vectors are lost by 
dilution. 
 
 
 
•Genomic 
integration. 
•Negative selection 
advised. 
 
•Genomic 
integration. 
•Negative selection 
advised. 
•Low efficiency. 
 
 
 
 
 
•Slow and inefficient. 
•Need to check 
numerous lines to 
find integration-free 
ones. 
•Labor-intensive.  
•Only for SV40T+ cell 
types.  
•Transgene-free and 
vector-free. 
•No genomic 
integration. 
•No need to screen 
numerous colonies. 
 
 
 
•Transgene-free and 
vector-free. 
•No genomic 
integration. 
•No need to screen 
numerous colonies. 
•Highest efficiency 
method. 
 
•Slow and inefficient. 
 
 
 
 
 
 
 
•Multiple 
transfections 
required. 
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•Latent retrovirus/lentivirus are a major risk for the medical use of iPSC. 
•Tumor generation. 
•Starting cell type differentiation level. 
•Variability problems and quality. 
•Chromosomal instability.  
•Low efficiency. 
•Mutagenesis owing to integrative methods. 
•Whole genome sequencing analysis. 
•Embryoid body formation. 
•Teratoma formation. 
•Alkaline phosphatase. 
•Methylation analysis (Differentially methylated regions). 
•Basic research: Differentiation, stem cell study and biological model. 
•Disease modeling: Study of disease physiopathology and personalized medicine. 
•Drug testing and personalized medicine: Test drug toxicity, doses, cell types affected as well as cellular response to a drug, resistance 
studies, alternative signaling pathways activation, correction of genetic mutations, etc. 
•Cellular therapy: Tissue regeneration, artificial organ production (or parts of an organ, such as artificial heart valves) and biological 
pacemakers. 
•Actually iPSCs generation methods are still not optimized and efficiency must be improved. 
•RNA delivery is by far the most efficient and safe method nowadays.  
•Using feeder layers is a problem for FDA/EMA approval of iPSC for regenerative medicine techniques. 
•Dedifferentiation mechanisms remain broadly unknown. 
•Two or more screening techniques are required for each iPSCs generation process. Since its use for 
medicine is the main goal, better screening  methods and biomarkers are required to be as close to 100% 
safety as possible, in order to avoid possible teratoma formation in the patient.  At this topic, 
transdifferentiation is safer and probably will replace iPSC for regenerative medicine.  
The proteins that trigger the first steps for iPSC 
generation are transcriptional factors. They can be 
combined in “cocktails” to success in this process. 
Here is shown a list with the most used nowadays 
and their main functions: 
•Sox2 Controls Oct3/4 expression. 
•Oct3/4 Essential for keeping pluripotency.  
•Klf4  Differentiation and cell proliferation. 
•c-Myc Proto-oncogene, increases 
efficiency.  
•NANOG Essential for dedifferentiation and 
X chromosome reactivation. 
•LIN28 Regulates self renewal. 
The process starts from a somatic cell and can 
not be any cell type. There are cells easier to 
extract from an animal and to reprogram: 
Low efficiencies during iPSC generation is the main problem of these methods. Small molecules can be 
used to improve it: 
•Histone deacetylase (HDAC) inhibitors: Valproic acid (VPA), butyrate and trichostatin A (TSA). 
•Methyltransferase inhibitors: BIX-01294 and Parnate. 
•MicroRNA blockers. 
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Figure 2: Steps that cells go through during the reprogramming process. There are 3 main steps and each one has 
specific characteristics such as phenotypic changes, transcriptional modifications, chromatin evens, 
dependence/independence of reprogramming factors and molecular requirements. SOURCE: “Progress in 
understanding reprogramming to the induced pluripotent state”. 
Figure 1: Different cell types sorted by its availability and 
ease of reprogramming. SOURCE: “Methods for making 
induced pluripotent stem cells: reprogramming à la carte” 
 
